Equities

Noile-Immune Biotech Inc

4893:TYO

Noile-Immune Biotech Inc

Actions
  • Price (JPY)185.00
  • Today's Change-16.00 / -7.96%
  • Shares traded2.98m
  • 1 Year change-58.71%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5,5564,5214,141
Total Receivables, Net67--53
Total Inventory213.934.27
Prepaid expenses685426
Other current assets, total5.565.301.17
Total current assets5,7174,5844,225
Property, plant & equipment, net--00
Goodwill, net------
Intangibles, net--00
Long term investments------
Note receivable - long term------
Other long term assets241919
Total assets5,7794,6414,271
LIABILITIES
Accounts payable------
Accrued expenses304620
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total5728960
Total current liabilities8633580
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total5.235.235.23
Total liabilities9134086
SHAREHOLDERS EQUITY
Common stock4,0462,7882,538
Additional paid-in capital4,0242,7652,515
Retained earnings (accumulated deficit)(2382)(1252)(868)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0--0.00
Total equity5,6874,3014,185
Total liabilities & shareholders' equity5,7794,6414,271
Total common shares outstanding434343
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.